Multicenter Retrospective Study to Evaluate Necitumumab plus Cisplatin/Gemcitabine after Immune-check-point inhibitors in Advanced Squamous-Cell Lung Cancer in Japan (NINJA study)

Multicenter Retrospective Study to Evaluate Necitumumab plus Cisplatin/Gemcitabine after Immune-check-point inhibitors in Advanced Squamous-Cell Lung Cancer in Japan (NINJA study) - Multicenter Retrospective Study to Evaluate Necitumumab plus Cisplatin/Gemcitabine after Immune-check-point inhibitors in Advanced Squamous-Cell Lung Cancer in Japan (NINJA study)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000048656

Enrollment

Registered

2022-08-12

Start date

2022-08-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced metastatic or recurrent Squamous-cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Histological or cytological diagnosis of Squamous-cell lung cancer Aged 20 years or older Advanced metastatic or recurrent stage Patients who received GCN therapy between 1 Nov. 2019 to 31 Mar. 2022 Patients who received ICIs before GCN therapy Patients who received GCN therapy by 4th line

Exclusion criteria

Exclusion criteria: Patients who received GCN therapy after 5th line Patients who participated in NESSIE trial (jRCTs051200138)

Design outcomes

Primary

Measure	Time frame
Progression-free survival (PFS)	—

Secondary

Measure	Time frame
Overall survival (OS) Time to Treatment Failure (TTF) Objective response rate (ORR) Disease control rate (DCR) Safety	—

Countries

Japan

Contacts

Public ContactShigeru Tanzawa

Department of Internal Medicine, Teikyo University School of Medicine Division of Medical Oncology

s.tanzawa@med.teikyo-u.ac.jp03-3964-1211

Outcome results